Jatt Ii Acquisition CORP Form 4 insider transactions

Talawar Tx Inc. CEO Marc Schegerin discussed the company's lead asset, TALA-125, an IL-18/IL-13 bispecific antibody for atopic dermatitis, highlighting its potential to break efficacy ceilings and its streamlined development path.

Talawar Tx Inc. details its lead bispecific antibody candidate, TALA-125, targeting IL-13 and IL-18 for immunology and inflammation diseases, with a planned Phase 1 trial start in Q1 2027.

JATT II Acquisition Corp. reports changes in beneficial ownership, with CEO Someit Sidhu's indirect holdings adjusted due to share forfeiture.

JATT Ventures II L.P. reports a forfeiture of 225,000 ordinary shares in JATT II Acquisition Corp. due to over-allotment option expiration.

Talawar Therapeutics is merging with JATT II Acquisition Corp in a SPAC deal, aiming to raise $285 million to advance its eczema asset TALA-125.

JATT II Acquisition Corp and Talawar Tx Inc. have entered into a business combination agreement, with JATT II becoming an indirect wholly-owned subsidiary of Talawar Tx Inc.

Talawar Therapeutics, a biotech company developing bispecific antibodies for I&I diseases, will combine with JATT II Acquisition Corp., a SPAC, to become a publicly listed company, with a $225 million PIPE financing.